[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628234":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":48,"responsibleParty":65,"collaborators":68,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":68,"enrollmentInfo":79,"targetDuration":68,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":51,"whyStopped":68,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Helsinki University Central Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients receiving active treatment","EXPERIMENTAL","CDI patients receiving healthy donor stool by capsules",[13],"Biological: Healthy donor stool",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo arm","PLACEBO_COMPARATOR","Placebo FMT capsules",[19],"Biological: placebo capsule",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Healthy donor stool","Healthy donor stool given by capsules produced by the same method as in Copenhagen University Hospital",[9],[27,28],"Fecal microbiota transplantation","FMT",{"type":22,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"placebo capsule","Copenhagen University Hvidrovre Hospital method for capsule production",[15],[17],[35],{"name":36,"affiliation":5,"role":37},"Perttu Arkkila, Professor","PRINCIPAL_INVESTIGATOR",[39,44],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+358504272272","+35894711","perttu.arkkila@hus.fi",{"name":45,"role":40,"phone":46,"phoneExt":42,"email":47},"Suvi Niku, PhD, MD","+35840 7579938","suvi.niku@hus.fi",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Helsinki University Hospital","RECRUITING","Helsinki","Uusimaa","00290","Finland","FI",{"type":58,"coordinates":59},"Point",[60,61],24.93545,60.16952,{"lat":61,"lon":60},[64],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":37,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":68,"oldOrganization":68},"Perttu Arkkila","Professor",null,"100628234","phase-3-fmt-capsules-for-rcdi-100628234",false,"NCT07458984","FMT Capsules for rCDI","Fecal Microbiota (FMT) Oral Capsules in the Treatment of Recurrent Clostridioides Difficile Infection","FMT CAP CDI","Inclusion Criteria:\n\n* At least twice recurrent CDI\\*\n* Patient has had CDI-related diarrhea during infections (3 or more Bristol Stool Form Scale type 6-7 stools)\n* Other causes of diarrhea have been excluded based on clinical data\n* Age over 18 years\n* Remission of symptoms during antibiotic course (metronidazole, vancomycin or fidaxomicin)\n* No other antibiotic courses\n* Able to sign the consent form or accept it electronically via Suomi.fi identification\n\n  * definition of recurrent CDI: CDI-compatible symptoms and a positive stool test Clostridioides difficile nucleic acid test within 12 weeks of the previous infection\n\nExclusion Criteria:\n\n* Pregnancy\n* Continuous need for antibiotic treatment\n* Previous anaphylactic reactions to any food\n* Gastroparesis\n* Life-threatening fulminant CDI\n* Life expectancy less than 1 year\n* Inability to sign a consent form for the study","ALL","18 Years",{"count":80,"type":81},76,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","Double blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.",[87,28],"Clostridioides Difficile Infection Recurrence",[89,28,90],"Clostridioides Difficile infection","Capsule","2026-04-24",{"date":93,"type":94},"2026-04-29","ACTUAL",{"date":96,"type":94},"2026-04-25",{"date":98,"type":81},"2030-12-31",{"name":5,"class":6},1]